Comparative Pharmacology
Head-to-head clinical analysis: MALARONE PEDIATRIC versus MEFLOQUINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MALARONE PEDIATRIC versus MEFLOQUINE HYDROCHLORIDE.
MALARONE PEDIATRIC vs MEFLOQUINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.
Mefloquine is a quinoline antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown but is thought to involve forming toxic heme complexes or inhibiting heme polymerase, leading to parasite death.
Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.
250 mg (1 tablet) orally once weekly for prophylaxis; 1250 mg (5 tablets) as a single oral dose for treatment of uncomplicated malaria.
None Documented
None Documented
Atovaquone: terminal half-life 1.5-3 days (range 2-3 days in adults, longer in children). Proguanil: terminal half-life 12-21 hours (parent drug) and 14-23 hours (cycloguanil). Clinically, atovaquone's long half-life supports single daily dosing.
~2-4 weeks (terminal half-life); clinical context: long half-life allows weekly dosing for prophylaxis, but accumulation can occur with repeated doses.
Atovaquone: >90% excreted unchanged in feces via biliary elimination; <1% renal. Proguanil: ~40-60% excreted renally as unchanged drug and active metabolite cycloguanil; ~30% fecal.
~83% (fecal/biliary), ~9% (renal unchanged), ~2.5% (renal as metabolite).
Category C
Category A/B
Antimalarial
Antimalarial